Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2′-deoxynucleoside triphosphates

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 12, 2000, Pages 3465-3472

  Meyer, P R ^a   Matsuura, S E ^a   Schinazi, R F ^a   So, A G ^a   Scott, W A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' DEOXYNUCLEOSIDE; 2',3' DIDEHYDRO 3' DEOXYTHYMIDINE 5' TRIPHOSPHATE; 3' AZIDO 3' DEOXYTHYMIDINE 5' MONOPHOSPHATE; 3' DEOXYTHYMIDINE 5' MONOPHOSPHATE; ADENOSINE TRIPHOSPHATE; DNA; NUCLEOTIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; THYMIDINE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS ENZYME; ZIDOVUDINE;

ARTICLE; CROSS RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS MUTANT; VIRUS RESISTANCE;

ADENOSINE TRIPHOSPHATE; DNA PRIMERS; HIV-1 REVERSE TRANSCRIPTASE; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; TEMPLATES, GENETIC; THYMIDINE MONOPHOSPHATE; THYMINE NUCLEOTIDES; ZIDOVUDINE;

EID: 0034425841     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.12.3465-3472.2000     Document Type: Article

References (39)

1. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): Increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase
2. On the fidelity of DNA replication: Lack of exodeoxyribonuclease activity and error-correction function in avian myeloblastosis virus DNA polymerase
3. Cell volumes and DNA distributions of normal and neoplastic human lymphoid cells
4. Sensitivity of HIV-1 reverse transcriptase and its mutants to inhibition by azidothymidine triphosphate
5. Cell volumes of normal and malignant mononuclear cells
6. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine
7. HIV-1 reverse transcriptase/ribonuclease H: High-level expression in Escherichia coli from a plasmid constructed using the polymerase chain reaction
8. Emergence of zidovudine resistance in HIV-infected patients receiving stavudine
9. Clinical HIV-1 isolates remain sensitive to stavudine following prolonged therapy
10. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells
11. Low levels of deoxynucleotides in peripheral blood lymphocytes: A strategy to inhibit human immunodeficiency virus type 1 replication
12. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
13. Kinetic mechanism of the DNA-dependent DNA polymerase activity of human immunodeficiency virus reverse transcriptase
14. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance
15. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine
16. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates
17. Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection
18. Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates
19. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture
20. Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay
21. Stavudine resistance: An update on susceptibility following prolonged therapy
22. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy
23. A mechanism of AZT resistance: An increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase
24. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism
25. Human immunodeficiency virusinfected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine
26. Phenotypic changes in drug susceptibility associated with the failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy
27. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy
28. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
29. Human immunodeficiency virus reverse transcriptase. A kinetic analysis of RNA-dependent and DNA-dependent DNA polymerization
30. The accuracy of reverse transcriptase from HIV-1
31. Simultaneous determination of pyrimidine or purine deoxyribonucleoside triphosphates using a polymerase assay
32. Mutations in retroviral genes associated with drug resistance: 2000-2001 Update
33. The measurement of lymphocyte volume: Importance of reference particle deformability and counting solution tonicity
34. Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells
35. Lack of emergence of genotypic resistance to stavudine after 2 years of monotherapy
36. Lymphocyte blastogenesis studied by volume spectroscopy
37. Pyrimidine nucleotide and nucleic acid synthesis in human monocytes and macrophages
38. Nucleotide-induced stable complex formation by HIV-1 reverse transcriptase
39. Mechanism of inhibition of the human immunodeficiency virus type 1 reverse transcriptase by d4TTP: An equivalent incorporation efficiency relative to the natural substrate dTTP